CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Insights on immunotherapy in pulmonary oncology
Authors
Perrine Canivet
Bernard DUYSINX
Renaud Louis
Frédérique VAILLANT
Publication date
22 August 2018
Publisher
Editions Medecine et Hygiene
Abstract
peer reviewedImmunotherapy, based on the immune response to tumor cells, gives a new therapeutic hope for lung cancer whose prognosis remains dark. Four molecules are currently available in clinical practice. They were first studied for non-small cell cancers in the second and third line of treatment with a significant improvement in overall survival, then in maintenance treatment and more recently in the front line with a significant response. Their complications, mainly dysimmune adverse effects, are protean but immunotherapy remains better tolerated than chemotherapy. It opens many perspectives but further studies, including biomarkers, are still needed. © 2018 Editions Medecine et Hygiene. All rights reserved
Similar works
Full text
Available Versions
Open Repository and Bibliography - Liège
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:orbi.ulg.ac.be:2268/240192
Last time updated on 18/10/2019